BPC-157 & TB-500 (Wolverine Stack) vs Liraglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157 & TB-500 (Wolverine Stack)
Known as the 'Wolverine Stack,' this popular combination pairs two powerful healing peptides. BPC-157 and TB-500 work synergistically to promote tissue repair, reduce inflammation, and accelerate recovery from injuries.
Full details →Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 & TB-500 (Wolverine Stack) | Liraglutide |
|---|---|---|
| Mechanism | BPC-157 upregulates growth factor expression and promotes angiogenesis, while TB-500 promotes cell migration and differentiation through actin regulation. Together, they enhance wound healing, reduce scar tissue formation, and support musculoskeletal recovery through complementary pathways. | Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects. |
| Typical Dosage | Typical research protocols: BPC-157 at 250-500mcg daily combined with TB-500 at 2-2.5mg twice weekly during loading phase, then 2mg every 2 weeks for maintenance. | Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily. |
| Administration | Both peptides administered via subcutaneous injection. Some protocols suggest injecting near injury sites for localized effects. Can be injected separately or as a pre-mixed blend. | Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications. |
| Side Effects | Generally well-tolerated. May include mild nausea, temporary fatigue, headache, or localized irritation at injection sites. | Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use. |
| Best For |